Oncology Analytics
Michael Weintraub is Co-Founder and Managing Partner of Ardan Equity Partners, a healthcare enterprise software private equity firm. Weintraub is Founding Chairman of Phreesia (NYSE: PHR), the leading patient intake company. Previously, Michael was Co-Founder and Managing Partner of Optum Ventures, focused on digital health innovation. Weintraub was Co-Founder and CEO of Humedica, a pioneer and leader in the the field of population health management and big data. Following Humedica’s acquisition by UnitedHealth Group (UHG), Michael broadened his role within UHG as President and CEO of Optum Analytics. Prior to launching Humedica, Weintraub was a Senior Managing Director at Leerink Partners (now SVB Leerink), a leading healthcare investment bank. Michael also was CEO of PharMetrics, a health care informatics company, which was acquired by IMS Health (now IQVIA). Weintraub currently serves as Chairman of BroadReach Healthcare, a global healthcare company based in Cape Town, South Africa. Michael serves as Chairman of Holmusk, a Behavioral Health Real World Evidence company. Weintraub is a member of the board of directors of Corrona, Oncology Analytics, NewFire Partners, and The College Diabetes Network (CDN). Michael also focuses on healthcare innovation as an Entrepreneur in Residence at Harvard Business School, and an Advisory Board member of the Innovation and Digital Health Accelerator at Boston Children’s Hospital. Weintraub received his Bachelor’s Degree in Economics from Brandeis University and an MBA from Harvard Business School.
This person is not in the org chart
This person is not in any offices
Oncology Analytics
Oncology Analytics, Inc. provides health plans with an evidence-based, technologically driven approach to utilization management, which is purpose-built for oncology. Used by physicians to support over 2.5 million health plan members in the US and Puerto Rico, the e-Prior Authorization platform is updated daily to accurately reflect more than 6,000 oncology treatment protocols for anti-cancer treatment across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy and supportive care